Nano Publications https://validator.w3.org/feed/docs/rss2.html 2010 – Concept of NBTXR3 – Borghi et al. OVERVIEW ALL 2021 – A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients 2021 – A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients 2021 – NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models 2021 – NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models 2021 – Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects 2021 – Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects 2021 – A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model 2021 – A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model 2020 – Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion 2020 – Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion ACCUEIL 2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets 2018 – ESMO 2018 – NBTXR3 in elderly HNSCC 2020 – ESMO – NBTXR3 in HCC and Liver Metastases 2020 – Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers 2020 – Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study 2020 – NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Cisplatin-Ineligible Patients With Locally Advanced HNSCC: A Phase I Trial 2021 – Eur J Surg Oncol – STS Retrospective Study 2021 – Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial 2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial 2021 – NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial 2021 – Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients 2021 – Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside 2020 – ASCO – NBTXR3 With Anti PD1 Therapy 2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis 2021 – NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial 2021 – Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice 2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial 2022 – NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma 2022 – NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma 2022 – Nanoparticle therapy for head and neck cancers 2022 – Nanoparticle therapy for head and neck cancers 2014 – Metals as Nanosized Radioenhancers – Pottier et al. 2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial 2020 – Int J Nanomedicine NBTXR3 Induces Abscopal Effect 2014 – Metals as Nanosized Radioenhancers – Pottier et al. 2019 – Bulletin Cancer – NBTXR3 improves pathological response 2020 – ASCO – NBTXR3 With Anti PD1 Therapy 2020 – Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study 2020 – NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study 2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy 2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy 2020 – Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers 2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial 2010 – Concept of NBTXR3 – Borghi et al. 2020 – Int J Nanomedicine NBTXR3 Induces Abscopal Effect 2021 – Eur J Surg Oncol – STS Retrospective Study 2019 – Bulletin Cancer – NBTXR3 improves pathological response